<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;div class="table-responsive"&gt;&lt;table class="table table-bordered" summary="This table shows the date, time, and location of the meeting"&gt;&lt;tbody&gt;&lt;/tbody&gt;&lt;thead&gt;&lt;tr class="text-center" style="background-color: #dddddd"&gt;&lt;th id="a1"&gt;Center&lt;/th&gt;&lt;th id="a2"&gt;Date&lt;/th&gt;&lt;th id="a3"&gt;Time&lt;/th&gt;&lt;th id="a4"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td headers="a1"&gt;NCTR&lt;/td&gt;&lt;td headers="a2"&gt;November 3, 2015&lt;br /&gt;November 4, 2015&lt;/td&gt;&lt;td headers="a3"&gt;12:30 p.m. -&amp;nbsp;5:00 p.m. CST&lt;br /&gt;8:00 a.m. - 5:00 p.m. CST&lt;/td&gt;&lt;td headers="a4"&gt;&lt;p&gt;NCTR SAB&lt;br /&gt;3900 NCTR Rd.&lt;br /&gt;Conference Room B-12&lt;br /&gt;Jefferson, AR 72079&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;h3&gt;Agenda&lt;/h3&gt;&lt;p&gt;On November 3, 2015, the SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the Division of Biochemistry Subcommittee and the Subcommittee Site Visit Report. Representatives from the Office of the Chief Scientist and Office of Medical Products and Tobacco will discuss research needs and opportunities for collaborations with NCTR.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;On November 4, 2015, the Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Center for Tobacco Products, Center for Veterinary Medicine, and Office of Regulatory Affairs will each briefly discuss their Center-specific research strategic needs. Following the public session, the SAB will hear an update from each of NCTR&amp;rsquo;s research divisions.&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Following an open discussion of all the information presented, the open session of the meeting will close so the SAB members can discuss personnel issues at NCTR at the end of each day.&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;h3&gt;Meeting Materials&lt;/h3&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Background material&amp;nbsp;&lt;br /&gt;&amp;nbsp;&lt;/li&gt;&lt;/ul&gt;&lt;h3&gt;Procedure&lt;/h3&gt;&lt;p&gt;On November 3, 2015, from 12:30 p.m. to&amp;nbsp;4:30 p.m., and November 4, 2015, from 8 a.m. to 4:15 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before October 27, 2015. Oral presentations from the public will be scheduled between approximately 11:45 a.m. and 12:45 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 19, 2015. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 20, 2015.&lt;/p&gt;&lt;h3&gt;Closed Committee Deliberations&lt;/h3&gt;&lt;p&gt;On November 4, 2015, from 4:15 p.m. to 5 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussions of information concerning individuals associated with the research programs at NCTR.&lt;/p&gt;&lt;p&gt;Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Donna Mendrick at least 7 days in advance of the meeting.&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at &lt;a target="" href="[!--$wcmUrl('link','UCM111462')--]"&gt;http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;h3&gt;Contact Information&lt;/h3&gt;&lt;p&gt;Donna Mendrick&lt;br /&gt;Food and Drug Administration&lt;br /&gt;10903 New Hampshire Ave.&lt;br /&gt;Bldg. 32, Room 2208&lt;br /&gt;Silver Spring, Maryland 20993-0002&lt;br /&gt;Phone: 301-796-8892&lt;br /&gt;&amp;nbsp;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
